Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Pete Stavropoulos
CANT
Pete Stavropoulos
Cantor Fitzgerald
Wall Street Analyst
★★★☆☆
#1769
on 13Foresight · ranked by our own returns
53%
Success Rate
+26.7%
Average Return
10 of 19 calls profitable · +10.8% vs benchmark
📈 Across the calls we could measure, roughly 53% of Pete Stavropoulos's ratings turned a profit when each position was held for 1 year — averaging +26.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

21 Buy 4 Hold 0 Sell
Pete's Stock Coverage 19 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
VERA
Vera Therapeutics
 Jun 04, 2026 BUY Strong Buy
+91.0% avg upside
19 analysts
$100.00
184.94% Upside
 -3.3%
AXSM
Axsome Therapeutics
 May 04, 2026 BUY Strong Buy
-10.5% avg upside
28 analysts
$272.00
8.49% Upside
 +12.6%
ALEC
Alector
 Apr 15, 2026 BUY Hold
+532.1% avg upside
14 analysts
 — -16.3%
RZLT
Rezolute
 Mar 25, 2026 HOLD Strong Buy
+122.8% avg upside
13 analysts
 — +5.0%
ALKS
Alkermes
 Mar 11, 2026 BUY Strong Buy
-17.6% avg upside
34 analysts
$43.00
4.37% Downside
 +63.3%
NVAX
Novavax
 Jan 13, 2026 BUY Buy
+154.1% avg upside
20 analysts
$18.00
97.21% Upside
 +2.4%
CRVO
CervoMed
 Dec 18, 2025 BUY Strong Buy
+398.6% avg upside
9 analysts
 — -62.8%
HELP
Helus Pharma
 Oct 15, 2025 BUY Strong Buy
+861.2% avg upside
12 analysts
 — ·
DNTH
Dianthus Therapeutics
 Aug 22, 2025 BUY Strong Buy
+8.8% avg upside
29 analysts
 — +224.6%
ELDN
Eledon Pharmaceuticals
 Jul 10, 2025 BUY Strong Buy
+302.0% avg upside
10 analysts
 — +10.1%
JSPR
Jasper Therapeutics
 Jul 07, 2025 HOLD Strong Buy
+6361.2% avg upside
17 analysts
 — -84.5%
DRUG
Bright Minds Biosciences
 Jul 02, 2025 BUY Strong Buy
+120.9% avg upside
10 analysts
 — +198.1%
ARCT
Arcturus Therapeutics
 Jul 01, 2025 BUY Buy
+290.9% avg upside
35 analysts
 — -35.3%
ANNX
Annexon Biosciences
 May 13, 2025 BUY Strong Buy
+181.2% avg upside
13 analysts
 — +211.4%
PLRX
Pliant Therapeutics
 Mar 03, 2025 HOLD Buy
+1821.1% avg upside
21 analysts
 — -9.4%
VYGR
Voyager Therapeutics
 Jan 10, 2025 BUY Strong Buy
+284.2% avg upside
23 analysts
 — -26.2%
VSTM
Verastem
 Aug 08, 2023 BUY Strong Buy
+260.2% avg upside
23 analysts
$34.00
725.25% Upside
 -77.7%
ABOS
Acumen Pharmaceuticals
 Aug 08, 2023 BUY Strong Buy
+258.9% avg upside
10 analysts
$13.00
475.24% Upside
 -60.9%
IMNM
Immunome
 Jun 23, 2023 HOLD Strong Buy
+83.0% avg upside
16 analysts
 — +123.3%
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Pete Stavropoulos — Frequently Asked Questions
How accurate are Pete Stavropoulos's stock ratings?
Based on the calls 13Foresight could measure, about 53% of Pete's ratings were profitable over a one-year hold, with an average return of +26.7% per rating, or +10.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Pete ranked on 13Foresight?
Pete Stavropoulos is currently ranked #1769 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Pete cover?
Pete most recently has ratings on VERA, AXSM, ALEC, RZLT, ALKS, NVAX, CRVO, HELP, DNTH, ELDN, JSPR, DRUG and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.